APA (7th ed.) Citation

Hermawan, A., & Putri, H. (2022). Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy. BMC Genomic Data, 23(1), 1. https://doi.org/10.1186/s12863-022-01086-2

Chicago Style (17th ed.) Citation

Hermawan, Adam, and Herwandhani Putri. "Bioinformatics Analysis Reveals the Potential Target of Rosiglitazone as an Antiangiogenic Agent for Breast Cancer Therapy." BMC Genomic Data 23, no. 1 (2022): 1. https://doi.org/10.1186/s12863-022-01086-2.

MLA (9th ed.) Citation

Hermawan, Adam, and Herwandhani Putri. "Bioinformatics Analysis Reveals the Potential Target of Rosiglitazone as an Antiangiogenic Agent for Breast Cancer Therapy." BMC Genomic Data, vol. 23, no. 1, 2022, p. 1, https://doi.org/10.1186/s12863-022-01086-2.